Mélida del Rosario Lizarazo Taborda

Dr. Mélida del Rosario Lizarazo Taborda


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MTMélida del Rosario Lizarazo Taborda
Mélida del Rosario Lizarazo Taborda
Juliana Marisol Godínez-RubíJuliana Marisol Godínez-Rubí
Juliana Marisol Godínez-Rubí
DNDaniel Nuñez
Daniel Nuñez
JAJorge Adrian Ramirez de Arellano
Jorge Adrian Ramirez de Arellano
APAna Laura Pereira-Suárez
Ana Laura Pereira-Suárez
JVJulio César Villegas-Pineda
Julio César Villegas-Pineda
Cervical cancer (CC) is the gynecological cancer with the highest incidence and mortality worldwide. High-risk oncogenic human papillomaviruses (HPV) genotypes 16 and 18 are the primary risk factors for developing this female neoplasm, with them being the etiological agents of 70% of cervical cancers. Despite the availability of various prevention strategies, laboratory tests capable of detecting the disease in its previous and early stages, and multiple treatment schemes, CC incidence and mortality rates remain high, due in part to the population’s rejection or disinterest in the current type of sampling. An alternative that could encourage women to take better care of their gynecological health is the availability of tests that detect biomarkers in non-cervical samples with high sensitivity and specificity. The detection of biomarkers in non-cervical samples (blood, serum, plasma, urine, and vaginal fluids) may help reduce the discomfort associated with cervical sampling in patients, therefore promoting gynecological healthcare. This review discusses current diagnostic methods and recent advances in CC biomarkers detected in non-cervical samples, emphasizing their potential for diagnosis, prognosis, and patient monitoring. We further discuss the challenges and future perspectives of applying these biomarkers in clinical practice. The results of this review show that there is a considerable range of biomarkers proposed as alternative tools with high efficacy. Their identification in previous stages of the disease and routinely in non-cervical samples could help reduce the incidence and mortality rates of CC.

1 April 2026 in Epigenomes
Verified
Journal Article
Open access
PDF file
MTMélida del Rosario Lizarazo Taborda
Mélida del Rosario Lizarazo Taborda
JVJulio César Villegas-Pineda
Julio César Villegas-Pineda
HJHolver Smith Parada Jurado
Holver Smith Parada Jurado
FGFabian Galvis
Fabian Galvis
JSJAVIER SOTO
JAVIER SOTO
Epithelial ovarian carcinoma (EOC) is the most common type of ovarian cancer and represents the most lethal gynecologic neoplasm. EOC is usually diagnosed at late stages due to its nonspecific signs and symptoms. Although significant clinical advances have been made in other types of malignancies, EOC remains a disease that requires further biological research to identify new therapeutic targets or new treatment alternatives, as conventional approaches are often ineffective or lead to the development of resistance and unwanted side effects. There are a significant number of natural products from which commercially available drugs have been derived, largely for the treatment of cancer, but none of them focus on epigenetic changes in specific targets in EOC. Based on the above, this work focuses on describing the in vitro and in vivo findings from the last twelve years derived from the action of important phytochemicals on epigenetic targets in ovarian cancer, among other mechanisms of action, revealing that there is a significant gap to be bridged in terms of the transition from basic to applied research regarding the potential of plant-derived molecules as possible epidrugs in EOC.